id: NEW:oliceridine_biased_opioid_agonism_to_NEW:opioid_related_side_effects
name: Oliceridine Biased Opioid Agonism â†’ Opioid-Related Side Effects
from_node:
  node_id: NEW:oliceridine_biased_opioid_agonism
  node_name: Oliceridine Biased Opioid Agonism
to_node:
  node_id: NEW:opioid_related_side_effects
  node_name: Opioid-Related Side Effects
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Oliceridine''s biased agonism reduces beta-arrestin recruitment compared to conventional opioids'
- 'Step 2: Reduced beta-arrestin signaling is hypothesized to decrease adverse effects such as respiratory
  depression, nausea, and constipation'
- 'Step 3: Lower side effect burden may improve postoperative recovery and reduce complications'
evidence:
  quality_rating: C
  n_studies: 0
  primary_citation: Anne Wolf et al. 2024. "Efficacy, safety, and side effects of oliceridine in acute
    postoperative pain, a protocol for a systematic review and meta-analysis." https://doi.org/10.1371/journal.pone.0299320
  supporting_citations:
  - Additional citations require full-text access - this is a protocol paper
  - Planned analysis will compare side effect profiles between oliceridine and morphine
  - Dose-dependent side effects to be evaluated via meta-regression
  doi: 10.1371/journal.pone.0299320
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The protocol plans to evaluate whether oliceridine's mechanism as a biased opioid agonist
  results in fewer side effects compared to conventional opioids like morphine. Dichotomous outcomes will
  be presented as risk ratios.
moderators:
- name: dose
  direction: u_shaped
  strength: moderate
  description: Side effects likely dose-dependent; meta-regression planned to characterize this relationship
structural_competency:
  equity_implications: Reduction in opioid side effects has structural implications for healthcare systems
    managing postoperative care. Populations with limited access to intensive monitoring (rural hospitals,
    under-resourced facilities) could particularly benefit from medications with improved safety profiles.
    However, cost and formulary access may create disparities in who receives newer, potentially safer
    medications.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:38.110259'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
